Literature DB >> 19720806

Medicines used in respiratory diseases only seen in children.

W Lenney1, A L Boner, L Bont, A Bush, K-H Carlsen, E Eber, B Fauroux, M Götz, A Greenough, J Grigg, J Hull, J Kimpen, M Sánchez Luna, F M de Benedictis.   

Abstract

Detailed literature searches were carried out in seven respiratory disease areas. Therapeutic evidence for efficacy of medicinal products was assessed using the Grades of Recommendation, Assessment and Evaluation (GRADE) methodology, as well as an assessment of safety and side-effects. Systemic corticosteroids may reduce the development of bronchopulmonary dysplasia but have serious side-effects. Antioxidants need further study to demonstrate whether they have long-term benefits. Treatments for acute bronchiolitis have shown little benefit but new antiviral and monoclonal antibodies need further assessment. Well-constructed studies are needed to confirm the value of inhaled corticosteroids and/or montelukast in the management of viral-induced wheeze. Corticosteroids are the treatment of choice in croup. Minimal or no information is available for the treatment of congenital lung abnormalities, bronchiolitis obliterans and interstitial lung disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19720806     DOI: 10.1183/09031936.00166508

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

1.  Clinical features of post-infectious bronchiolitis obliterans in children undergoing long-term azithromycin treatment.

Authors:  Xueyan Wang; Changshan Liu; Mengjuan Wang; Y I Zhang; Hewen Li; Geli Liu
Journal:  Exp Ther Med       Date:  2015-04-08       Impact factor: 2.447

Review 2.  Endpoints in respiratory diseases.

Authors:  Fernando Maria de Benedictis; Roberto Guidi; Silvia Carraro; Eugenio Baraldi
Journal:  Eur J Clin Pharmacol       Date:  2010-11-23       Impact factor: 2.953

Review 3.  Plant-Derived Natural Products as Lead Agents against Common Respiratory Diseases.

Authors:  Ayodeji Oluwabunmi Oriola; Adebola Omowunmi Oyedeji
Journal:  Molecules       Date:  2022-05-10       Impact factor: 4.927

Review 4.  Update on leukotriene receptor antagonists in preschool children wheezing disorders.

Authors:  Silvia Montella; Marco Maglione; Sara De Stefano; Angelo Manna; Angela Di Giorgio; Francesca Santamaria
Journal:  Ital J Pediatr       Date:  2012-06-26       Impact factor: 2.638

5.  Treatment of acute viral bronchiolitis.

Authors:  Ernst Eber
Journal:  Open Microbiol J       Date:  2011-12-30

6.  Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants.

Authors:  Eugenio Baraldi; Marcello Lanari; Paolo Manzoni; Giovanni A Rossi; Silvia Vandini; Alessandro Rimini; Costantino Romagnoli; Pierluigi Colonna; Andrea Biondi; Paolo Biban; Giampietro Chiamenti; Roberto Bernardini; Marina Picca; Marco Cappa; Giuseppe Magazzù; Carlo Catassi; Antonio Francesco Urbino; Luigi Memo; Gianpaolo Donzelli; Carlo Minetti; Francesco Paravati; Giuseppe Di Mauro; Filippo Festini; Susanna Esposito; Giovanni Corsello
Journal:  Ital J Pediatr       Date:  2014-10-24       Impact factor: 2.638

Review 7.  Interstitial Lung Disease in Childhood: Clinical and Genetic Aspects.

Authors:  Hiroshi Kitazawa; Shigeo Kure
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-10-11

8.  Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study.

Authors:  Maarten O Blanken; Hendrik Koffijberg; Elisabeth E Nibbelke; Maroeska M Rovers; Louis Bont
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

9.  IL1RL1 gene variants and nasopharyngeal IL1RL-a levels are associated with severe RSV bronchiolitis: a multicenter cohort study.

Authors:  Tina E Faber; Annemieke Schuurhof; Annelies Vonk; Gerard H Koppelman; Marije P Hennus; Jan L L Kimpen; Riny Janssen; Louis J Bont
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.